Article Information
Group Information: The members of the Translational Biomarkers in Aging and Dementia (TRIAD) study,
Alzheimer’s and Families (ALFA) study, and BioCogBank Paris Lariboisière cohort are
listed in Supplement 2.
Accepted for Publication: August 16, 2021.
Published Online: October 18, 2021. doi:10.1001/jamaneurol.2021.3671
Open Access: This is an open access article distributed under the terms of the
CC-BY License. © 2021 Benedet AL et al.
JAMA Neurology.
Corresponding Authors: Kaj Blennow, MD, PhD, Institute of Neuroscience and Physiology, Department of Psychiatry
and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, SE 43180 Gothenburg,
Sweden (
kaj.blennow@
123456neuro.gu.se
); Marc Suárez-Calvet, MD, PhD, Alzheimer Prevention Program–Barcelonaßeta Brain Research
Center, Wellington 30, 08005 Barcelona, Spain (
msuarez@
123456barcelonabeta.org
).
Author Contributions: Drs Blennow and Suárez-Calvet had full access to all of the data in the study and
take responsibility for the integrity of the data and the accuracy of the data analysis.
Dr Benedet, Ms Milà-Alomà, and Dr Vrillon contributed equally to this work. Drs Paquet,
Rosa-Neto, Blennow, and Suárez-Calvet are equal co–senior authors on this work.
Concept and design: Benedet, Milà-Alomà, Vrillon, Ashton, Karikari, Minguillon, Zetterberg, Molinuevo,
Rosa-Neto, Suárez-Calvet.
Acquisition, analysis, or interpretation of data: Benedet, Milà-Alomà, Vrillon, Ashton, Pascoal, Lussier, Karikari, Hourregue, Cognat,
Dumurgier, Stevenson, Rahmouni, Pallen, Poltronetti, Salvadó, Shekari, Operto, Gispert,
Fauria, Kollmorgen, Suridjan, Zimmer, Zetterberg, Paquet, Rosa-Neto, Blennow, Suárez-Calvet.
Drafting of the manuscript: Benedet, Milà-Alomà, Vrillon, Ashton, Pallen, Paquet, Rosa-Neto, Suárez-Calvet.
Critical revision of the manuscript for important intellectual content: Benedet, Milà-Alomà, Vrillon, Ashton, Pascoal, Lussier, Karikari, Hourregue, Cognat,
Dumurgier, Stevenson, Rahmouni, Poltronetti, Salvadó, Shekari, Operto, Gispert, Minguillon,
Fauria, Kollmorgen, Suridjan, Zimmer, Zetterberg, Molinuevo, Rosa-Neto, Blennow, Suárez-Calvet.
Statistical analysis: Benedet, Milà-Alomà, Ashton, Salvadó, Gispert, Rosa-Neto, Suárez-Calvet.
Obtained funding: Gispert, Suridjan, Molinuevo, Rosa-Neto, Blennow, Suárez-Calvet.
Administrative, technical, or material support: Benedet, Pascoal, Lussier, Karikari, Stevenson, Rahmouni, Operto, Fauria, Kollmorgen,
Suridjan, Zetterberg, Paquet, Rosa-Neto, Suárez-Calvet.
Supervision: Ashton, Minguillon, Molinuevo, Rosa-Neto, Blennow, Suárez-Calvet.
Conflict of Interest Disclosures: Dr Vrillon reported receiving grants from Fondation Ophtalmologique Adolphe de Rothschild,
Fondation Philipe Chatrier, Amicale des Anciens Internes des Hôpitaux de Paris, and
Fondation Vaincre Alzheimer during the conduct of the study. Dr Gispert reported receiving
grants from GE Healthcare, Roche Diagnostics, and F. Hoffman-La Roche; and speaker’s
fees from Philips and Biogen during the conduct of the study. Dr Suridjan reported
being an employee of and owning stocks in Roche Diagnostics. Dr Zetterberg reported
receiving personal fees from Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed,
Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, CogRx, Red Abbey
Labs, Cellectricon, Alzecure, Fujirebio, and Biogen and also reported being cofounder
of and holding stock in Brain Biomarker Solutions in Gothenburg AB outside the submitted
work. Dr Molinuevo reported receiving in-kind reagents from Roche Diagnostics and
GE Healthcare and grants from “La Caixa” Foundation NA and Alzheimer’s Association
NA during the conduct of the study as well as being an employee of Lundbeck A/S and
serving on the advisory board for Genentech, Roche Diagnostics, Novartis, Genentech,
Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, BioCross, and ProMis
Neurosciences outside the submitted work. Dr Paquet reported receiving personal fees
from Roche, Biogen, and Lilly during the conduct of the study. Dr Blennow reported
personal fees from Abcam, Axon, Biogen, JOMDD/Shimadzu, Lilly, MagQu, Novartis, Roche
Diagnostics, and Siemens outside the submitted work and being cofounder of Brain Biomarker
Solutions in Gothenburg AB, which is a part of the GU Ventures Incubator Program.
Dr Suárez-Calvet reported receiving personal fees from Roche Diagnostics International
and Roche Farma, SA outside the submitted work. No other disclosures were reported.
Funding/Support: The Translational Biomarkers in Aging and Dementia (TRIAD) is supported by the Canadian
Institutes of Health Research (MOP-11-51-31; RFN 152985, 159815, 162303); Canadian
Consortium of Neurodegeneration and Aging (MOP-11-51-31 -team 1); Weston Brain Institute,
Brain Canada Foundation (Canadian Foundation for Innovation Project 34874; 33397),
and the Fonds de Recherche du Québec–Santé (Chercheur Boursier, 2020-VICO-279314).
The Alzheimer’s and Families (ALFA) study receives funding from “La Caixa” Foundation
(LCF/PR/GN17/10300004) and the Alzheimer’s Association and an international anonymous
charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17-519007).
Dr Benedet is supported by the Swedish Alzheimer Foundation, Stiftelsen för Gamla
Tjänarinnor, and Stohne Stiftelsen. Dr Vrillon is supported by Fondation Adolphe de
Rotschild, Fondation Philippe Chatrier, Association des Anciens Internes des Hôpitaux
de Paris, Fondation Vaincre Alzheimer, Stiftelsen för Gamla Tjänarinnor, Demensfundet,
and Stohne Stiftelsen. Dr Zetterberg is a Wallenberg Scholar supported by grants from
the Swedish Research Council (grant 2018-02532), the European Research Council (grant
681712), Swedish State Support for Clinical Research (grant ALFGBG-720931), the Alzheimer
Drug Discovery Foundation (ADDF) (grant 201809-2016862), the Alzheimer Disease (AD)
Strategic Fund and the Alzheimer’s Association (grants ADSF-21-831376-C, ADSF-21-831381-C,
and ADSF-21-831377-C), the Olav Thon Foundation, the Erling-Persson Family Foundation,
Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden (grant FO2019-0228), the European
Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie
grant agreement No 860197 (MIRIADE), and the UK Dementia Research Institute at University
College London. Dr Blennow is supported by the Swedish Research Council (grant 2017-00915),
the ADDF (grant RDAPB-201809-2016615), the Swedish Alzheimer Foundation (grant AF-742881),
Hjärnfonden, Sweden (grant FO2017-0243), the Swedish state under the agreement between
the Swedish government and the County Councils, the Avtal om Läkarutbildning och Forskining
agreement (grant ALFGBG-715986), the European Union Joint Program for Neurodegenerative
Disorders (grant JPND2019-466-236), and the National Institutes of Health (grant 1R01AG068398-01).
Dr Suárez-Calvet receives funding from the European Research Council under the European
Union’s Horizon 2020 research and innovation programme (grant 948677), the Instituto
de Salud Carlos III (grant PI19/00155), and the Spanish Ministry of Science, Innovation
and Universities (Juan de la Cierva Programme grant IJC2018-037478-I).
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection,
management, analysis, and interpretation of the data; preparation, review, or approval
of the manuscript; and decision to submit the manuscript for publication.
Group Information: The members of the TRIAD study, ALFA study, and BioCogBank Paris Lariboisière cohort
are listed in
Supplement 2.
Additional Contributions: The authors would like to express their most sincere gratitude to the TRIAD, ALFA,
and BioCogBank Paris project participants and relatives without whom this research
would have not been possible. The authors thank all of the staff at the University
of Gothenburg, Sahlgrenska University Hospital, McGill University Research Centre
for Studies, and Montreal Neurological Institute who supported this project. The authors
thank Roche Diagnostics International Ltd for providing the kits to measure cerebrospinal
fluid biomarkers, Cerveau Technologies for MK-6240, and GE Healthcare for the [
18F]flutemetamol doses for ALFA+ study participants.
Additional Information: This publication is part of the TRIAD, the ALFA, and the BioCogBank Paris Lariboisière
studies. ELECSYS, COBAS, and COBAS E are trademarks of Roche. The Roche NeuroToolKit
is a panel of exploratory prototype assays designed to robustly evaluate biomarkers
associated with key pathologic events characteristic of Alzheimer disease and other
neurologic disorders, used for research purposes only and not approved for clinical
use. All requests for raw and analyzed data and materials will be promptly reviewed
by the senior authors to verify whether the request is subject to any intellectual
property or confidentiality obligations. Bulk anonymized data can be shared by request
from any qualified investigator for the sole purpose of replicating procedures and
results presented in the article, providing data transfer is in agreement with European
Union legislation and decisions by the institutional review board of each participating
center.